No Data
No Data
CanSino Biologics Inc.'s (HKG:6185) Shares Bounce 37% But Its Business Still Trails The Industry
Most pharmaceutical stocks rose, with Tongyuan Kangyi Medicine (02410) up 18.46%. Institutions pointed out that the policy trend of medical insurance funds supporting innovative drugs will not change.
Jingwu Cai Xun | Most pharmaceutical stocks rose, with Tongyuan Kang Medicine (02410) up 18.46%, Keji Pharmaceutical (02171) up 13.86%, Heyu (02256) up 11.79%, Cloud Peak Xin Yao (01952) up 10.31%, cansinobio (06185) up 7.48%. Zhong Yin International stated that benefiting from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity industry, is expected to outperform the market. The bank believes that the performance of the macroeconomy is closely related to the revenue and expenditure of medical insurance funds and medical health consumer spending. As policy focus shifts to stimulating the economy, the bank believes that medical industry
Results: CanSino Biologics Inc. Confounded Analyst Expectations With A Surprise Profit
Third Quarter Report 2024
Cansino Biologics Inc. (688185.SH) released its performance for the first three quarters, with a net loss of 0.222 billion yuan.
Cansino Biologics Inc. (688185.SH) released the third quarter report for 2024, with a revenue of 5.6...
CanSino Biologics Logs 3 Million Yuan of Net Attributable Profit for Q3
No Data
No Data